Q4 2025 Viatris Inc Earnings Call Transcript
Key Points
- Viatris Inc (VTRS) reported strong commercial performance in 2025 with total revenues of $14.3 billion, representing approximately 2% growth compared to 2024.
- The company achieved significant regulatory progress with 5 positive Phase III readouts and advanced its pipeline, including full enrollment expected for armod and selatogrel Phase III trials in 2026.
- Viatris Inc (VTRS) returned over $1 billion to shareholders through dividends and share repurchases, demonstrating a commitment to capital return.
- The company completed 60 regional transactions, including the acquisition of Aculys Pharma in Japan, targeting accretive regional business development.
- A strategic review identified approximately $650 million in gross cost savings over three years, with plans to reinvest up to $250 million to enhance growth and competitiveness.
- The Indore facility faced challenges, with the timing for FDA reinspection remaining uncertain, although operational redundancies and alternative supply sources have been established.
- The company anticipates a modest decline in gross margins in 2026 due to anticipated losses of exclusivity and mix shifts.
- Viatris Inc (VTRS) expects regulatory pricing challenges in Japan, impacting revenue and EBITDA due to mandatory price decreases on LOE products.
- The company faces competitive impacts in North America, including the loss of exclusivity for certain products.
- Free cash flow in 2026 will be impacted by transaction-related and restructuring costs from the strategic review.
Good morning, and welcome to the Viatris Q4 2025 earnings call. (Operator Instructions) Please note that today's event is being recorded.
I would now like to turn the conference over to Mr. Bill Szablewski, Head of Capital Markets. Please go ahead
Good morning, everyone. Welcome to our Q4 2025 earnings call. With us today is our CEO, Scott Smith; CFO, Theodora Mistras, Chief R&D Officer, Philippe Martin; and Chief Commercial Officer, Corinne Le Goff.
During today's call, we will be making forward-looking statements on a number of matters, including our financial guidance for 2026 and various strategic initiatives. Those statements are subject to risks and uncertainties. We will also be referring to certain actual and projected non-GAAP financial measures. Please refer to today's slide presentation and our SEC filings for more information, including reconciliations for those non-GAAP measures to the most directly comparable GAAP measures.
When discussing 2025 actual or
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
